Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

January 4, 2023

Study Completion Date

January 4, 2023

Conditions
Diabetic Nephropathy
Interventions
DRUG

HEC73077 tablets

"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."

DRUG

HEC73077 placebo tablets

"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."

Trial Locations (1)

130000

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY